 |
|
Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics
Michel R. Mandel, MD;
Joanne B. Severe, MS;
Nina R. Schooler, PhD;
Alan J. Gelenberg, MD;
Marlene Mieske, RN, MS
Arch Gen Psychiatry. 1982;39(2):197-203.
Abstract
• Data were collected during a year-long multicenter collaborative trial comparing short-acting fluphenazine hydrochloride with long-acting fluphenazine decanoate in a group of schizophrenic patients being maintained in the community. We examined the emergence and course of depressive symptomatology, operationally defined by the Hamilton Depression Scale total score. Of 211 patients, approximately 25% had depression develop within five months after discharge. Depressed patients had a more chronic psychiatric history and, contrary to the hypothesis that depression is a favorable prognostic indicator, they were more likely to relapse. There were no differences in incidence of emergent depression between the two drug treatment groups.
Author Affiliations
From the Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, and Erich Lindemann Mental Health Center, Boston (Drs Mandel and Gelenberg and Ms Mieske); and the Pharmacologie and Somatic Treatments Research Branch, National Institute of Mental Health, Rockville, Md (Dr Schooler and Ms Severe). Dr Mandel is now with the Department of Psychological Medicine, Pacific Medical Center, San Francisco.
Footnotes
Accepted for publication Aug 24, 1981.
Read before the New Clinical Drug Evaluation Unit Meeting, Key Biscayne, Fla, May 28, 1981.
Reprint requests to 5600 Fishers Lane, Room 10C06, Rockville, MD 20857 (Dr Schooler).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Historical perspective on antipsychotic long-acting injections
Johnson
Br. J. Psychiatry 2009;195:S7-S12.
ABSTRACT
| FULL TEXT
Psychiatric Comorbidities and Schizophrenia
Buckley et al.
Schizophr Bull 2009;35:383-402.
ABSTRACT
| FULL TEXT
Differential Effect of Quetiapine on Depressive Symptoms in Patients with Partially Responsive Schizophrenia
Emsley et al.
J Psychopharmacol 2003;17:210-215.
ABSTRACT
Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents
Siris
Am. J. Psychiatry 2000;157:1379-1389.
ABSTRACT
| FULL TEXT
Antidepressants in 'Depressed' Schizophrenic Inpatients: A Controlled Trial
Kramer et al.
Arch Gen Psychiatry 1989;46:922-928.
ABSTRACT
Cholinergic Hyperactivity and Negative Schizophrenic Symptoms: A Model of Cholinergic/Dopaminergic Interactions in Schizophrenia
Tandon and Greden
Arch Gen Psychiatry 1989;46:745-753.
ABSTRACT
Adjunctive Imipramine in the Treatment of Postpsychotic Depression: A Controlled Trial
Siris et al.
Arch Gen Psychiatry 1987;44:533-539.
ABSTRACT
{alpha}-Adrenergic Receptor Function in Schizophrenia: Receptor Number, Cyclic Adenosine Monophosphate Production, Adenylate Cyclase Activity, and Effect of Drugs
Kafka and van Kammen
Arch Gen Psychiatry 1983;40:264-270.
ABSTRACT
|
